Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

NextCure, Inc. (NXTC)

1.37   -0.03 (-2.14%) 12-06 09:41
Open: 1.4 Pre. Close: 1.4
High: 1.385 Low: 1.37
Volume: 5,897 Market Cap: 38(M)

Technical analysis

as of: 2022-12-06 9:20:51 AM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 2.41     One year: 2.99
Support: Support1: 1.25    Support2: 1.04
Resistance: Resistance1: 2.06    Resistance2: 2.55
Pivot: 1.47
Moving Average: MA(5): 1.38     MA(20): 1.52
MA(100): 3.26     MA(250): 4.23
MACD: MACD(12,26): -0.3     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 26.8     %D(3): 25
RSI: RSI(14): 26.5
52-week: High: 6.48  Low: 1.25
Average Vol(K): 3-Month: 113 (K)  10-Days: 99 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ NXTC ] has closed above bottom band by 31.2%. Bollinger Bands are 60% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.42 - 1.43 1.43 - 1.44
Low: 1.35 - 1.36 1.36 - 1.37
Close: 1.39 - 1.4 1.4 - 1.41

Company Description

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Headline News

Mon, 28 Nov 2022
Jon Soderstrom Joins Wilson Sonsini as Chief Licensing Advisor - The Bakersfield Californian

Tue, 22 Nov 2022
NextCure to Present at Upcoming Investor Conferences | News | bakersfield.com - The Bakersfield Californian

Tue, 22 Nov 2022
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate - Simply Wall St

Tue, 15 Nov 2022
NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates - Yahoo Finance

Mon, 07 Nov 2022
NextCure (NXTC) Presents Initial Data from Clinical Trial of NC762 - StreetInsider.com

Thu, 03 Nov 2022
NextCure Provides Update and Reports Third Quarter 2022 Financial Results - Yahoo Finance

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 28 (M)
Shares Float 17 (M)
% Held by Insiders 8.7 (%)
% Held by Institutions 61.6 (%)
Shares Short 475 (K)
Shares Short P.Month 588 (K)

Stock Financials

EPS -2.66
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.53
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -21
Return on Equity (ttm) -34.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.15
Sales Per Share 0
EBITDA (p.s.) -2.45
Qtrly Earnings Growth 0
Operating Cash Flow -58 (M)
Levered Free Cash Flow -32 (M)

Stock Valuations

PE Ratio -0.53
PEG Ratio 0
Price to Book value 0.21
Price to Sales 0
Price to Cash Flow -0.67

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.